Design, Synthesis, and Biological Evaluation of Some Novel Pyrrolizine Derivatives As COX Inhibitors with Anti-Inflammatory/Analgesic Activities and Low Ulcerogenic Liability

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2016 Feb 12

PMID 26867188

Citations 8

Authors

Ahmed M Gouda

Hamed I Ali

Waleed H Almalki

Mohamed A Azim

Mohammed A S Abourehab

Ahmed H Abdelazeem

Affiliations

Soon will be listed here.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed anti-inflammatory and pain relief medications. However, their use is associated with many drawbacks, including mainly serious gastric and renal complications. In an attempt to circumvent these risks, a set of N-(4-bromophenyl)-7-cyano-6-substituted-H-pyrrolizine-5-carboxamide derivatives were designed, synthesized and evaluated as dual COX/5-LOX inhibitors. The structural elucidation, in vivo anti-inflammatory and analgesic activities using a carrageenan-induced rat paw edema model and hot plate assay, were performed, respectively. From the results obtained, it was found that the newly synthesized pyrrolizines exhibited IC50 values in the range of 2.45-5.69 µM and 0.85-3.44 µM for COX-1 and COX-2, respectively. Interestingly, compounds 12, 13, 16 and 17 showed higher anti-inflammatory and analgesic activities compared to ibuprofen. Among these derivatives, compounds 16 and 19 displayed better safety profile than ibuprofen in acute ulcerogenicity and histopathological studies. Furthermore, the docking studies revealed that compound 17 fits nicely into COX-1 and COX-2 binding sites with the highest binding affinity, while compound 16 exerted the highest binding affinity for 5-LOX. In light of these findings, these novel pyrrolizine-5-carboxamide derivatives represent a promising scaffold for further development into potential dual COX/5-LOX inhibitors with safer gastric profile.

Citing Articles

NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead.

Khalil N, Ahmed E, Tharwat T, Mahmoud Z RSC Adv. 2024; 14(42):30647-30661.

PMID: 39324041 PMC: 11423417. DOI: 10.1039/d4ra04686b.

Pyrrolizine/Indolizine-NSAID Hybrids: Design, Synthesis, Biological Evaluation, and Molecular Docking Studies.

Abourehab M, Alqahtani A, Almalki F, Zaher D, Abdalla A, Gouda A Molecules. 2021; 26(21).

PMID: 34770990 PMC: 8588198. DOI: 10.3390/molecules26216582.

Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds.

Petri G, Raimondi M, Spano V, Holl R, Barraja P, Montalbano A Top Curr Chem (Cham). 2021; 379(5):34.

PMID: 34373963 PMC: 8352847. DOI: 10.1007/s41061-021-00347-5.

Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities.

Shawky A, Ibrahim N, Abourehab M, Abdalla A, Gouda A J Enzyme Inhib Med Chem. 2020; 36(1):15-33.

PMID: 33103497 PMC: 7594867. DOI: 10.1080/14756366.2020.1837124.

Investigation of the curative effects of palm vitamin E tocotrienols on autoimmune arthritis disease in vivo.

Zainal Z, Abdul Rahim A, Radhakrishnan A, Chang S, Khazaai H Sci Rep. 2019; 9(1):16793.

PMID: 31727971 PMC: 6856359. DOI: 10.1038/s41598-019-53424-7.

References

Jett M, Ramesha C, Brown C, Chiu S, Emmett C, Voronin T . Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther. 1999; 288(3):1288-97. View

Lashbrook J, Ossipov M, Hunter J, Raffa R, Tallarida R, Porreca F . Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. Pain. 1999; 82(1):65-72. DOI: 10.1016/S0304-3959(99)00031-7. View

Inagaki M, Tsuri T, Jyoyama H, Ono T, Yamada K, Kobayashi M . Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. J Med Chem. 2000; 43(10):2040-8. DOI: 10.1021/jm9906015. View

Selinsky B, Gupta K, Sharkey C, Loll P . Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry. 2001; 40(17):5172-80. DOI: 10.1021/bi010045s. View

Tomisato W, Tsutsumi S, Rokutan K, Tsuchiya T, Mizushima T . NSAIDs induce both necrosis and apoptosis in guinea pig gastric mucosal cells in primary culture. Am J Physiol Gastrointest Liver Physiol. 2001; 281(4):G1092-100. DOI: 10.1152/ajpgi.2001.281.4.G1092. View

Ulbrich H, Fiebich B, Dannhardt G . Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H-dihydropyrrolizine type. Eur J Med Chem. 2003; 37(12):953-9. DOI: 10.1016/s0223-5234(02)01418-6. View

Chiroli V, Benedini F, Ongini E, Del Soldato P . Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin. Eur J Med Chem. 2003; 38(4):441-6. DOI: 10.1016/s0223-5234(03)00055-2. View

Eddy N, Leimbach D . Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther. 1953; 107(3):385-93. View

WINTER C, RISLEY E, NUSS G . Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962; 111:544-7. DOI: 10.3181/00379727-111-27849. View

10.

Praveen Rao P, Amini M, Li H, Habeeb A, Knaus E . Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J Med Chem. 2003; 46(23):4872-82. DOI: 10.1021/jm0302391. View

11.

Tomisato W, Tsutsumi S, Hoshino T, Hwang H, Mio M, Tsuchiya T . Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem Pharmacol. 2004; 67(3):575-85. DOI: 10.1016/j.bcp.2003.09.020. View

12.

Cryer B . NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am J Gastroenterol. 2005; 100(8):1694-5. DOI: 10.1111/j.1572-0241.2005.50565.x. View

13.

Mounier G, Guy C, Berthoux F, Beyens M, Ratrema M, Ollagnier M . [Severe renal adverse events with arylcarboxylic non-steroidal anti-inflammatory drugs: results of a eight-year French national survey]. Therapie. 2006; 61(3):255-66. View

14.

Schneider V, Levesque L, Zhang B, Hutchinson T, Brophy J . Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. 2006; 164(9):881-9. DOI: 10.1093/aje/kwj331. View

15.

Liedtke A, Keck P, Lehmann F, Koeberle A, Werz O, Laufer S . Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J Med Chem. 2009; 52(15):4968-72. DOI: 10.1021/jm900481c. View

16.

Yeomans N, Hawkey C, Brailsford W, Naesdal J . Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs. Curr Med Res Opin. 2009; 25(11):2785-93. DOI: 10.1185/03007990903212682. View

17.

Abbas S, Awadallah F, Ibrahim N, Gouda A . Novel substituted and fused pyrrolizine derivatives: synthesis, anti-inflammatory and ulcerogenecity studies. Eur J Med Chem. 2009; 45(2):482-91. DOI: 10.1016/j.ejmech.2009.10.031. View

18.

Gilbert N, Bartlett S, Waight M, Neau D, Boeglin W, Brash A . The structure of human 5-lipoxygenase. Science. 2011; 331(6014):217-9. PMC: 3245680. DOI: 10.1126/science.1197203. View

19.

Liu W, Zhou J, Bensdorf K, Zhang H, Liu H, Wang Y . Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives. Eur J Med Chem. 2011; 46(3):907-13. DOI: 10.1016/j.ejmech.2011.01.002. View

20.

Gilbert N, Rui Z, Neau D, Waight M, Bartlett S, Boeglin W . Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663. FASEB J. 2012; 26(8):3222-9. PMC: 3405276. DOI: 10.1096/fj.12-205286. View